RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers

被引：0

作者：

Emma Nolan

François Vaillant

Daniel Branstetter

Bhupinder Pal

Göknur Giner

Lachlan Whitehead

Sheau W Lok

Gregory B Mann

Kathy Rohrbach

Li-Ya Huang

Rosalia Soriano

Gordon K Smyth

William C Dougall

Jane E Visvader

Geoffrey J Lindeman

机构：

[1] Walter and Eliza Hall Institute of Medical Research (WEHI),ACRF Stem Cells and Cancer Division

[2] University of Melbourne,Department of Medical Biology

[3] Amgen Inc.,Department of Pathology

[4] Walter and Eliza Hall Institute of Medical Research,Bioinformatics Division

[5] Imaging Laboratory,Systems Biology and Personalized Medicine Division

[6] Walter and Eliza Hall Institute of Medical Research,Department of Medical Oncology

[7] Familial Cancer Centre,Department of Surgery

[8] Royal Melbourne Hospital,Department of Mathematics and Statistics

[9] Royal Melbourne Hospital,Department of Medicine

[10] The Breast Service,undefined

[11] Royal Melbourne Hospital and Royal Women's Hospital,undefined

[12] University of Melbourne,undefined

[13] University of Melbourne,undefined

[14] Therapeutic Innovation Unit,undefined

[15] Amgen Inc.,undefined

[16] University of Melbourne,undefined

[17] Familial Cancer Centre,undefined

[18] Victorian Comprehensive Cancer Centre,undefined

[19] Present addresses: Cynosure Clinical Research LLC,undefined

[20] North Bend,undefined

[21] Washington,undefined

[22] USA (D.B.); Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute,undefined

[23] Herston,undefined

[24] Queensland,undefined

[25] Australia (W.C.D.).,undefined

来源：

Nature Medicine | 2016年 / 22卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A new study by Jane Visvader, Geoff Lindeman and colleagues reports on the potential role of RANK signaling in pre-neoplastic breast tissue from BRCA1-mutation carriers and in a mouse model of Brca1-deficient mammary cancer, suggesting that targeting RANK could be explored as an approach to prevent growth of tumors harboring mutated BRCA1.

引用

页码：933 / 939

页数：6

共 50 条

[1] RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
Nolan, Emma
Vaillant, Francois
Branstetter, Daniel
Pal, Bhupinder
Giner, Goeknur
Whitehead, Lachlan
Lok, Sheau W.
Mann, Gregory B.
Rohrbach, Kathy
Huang, Li-Ya
Soriano, Rosalia
Smyth, Gordon K.
Dougall, William C.
Visvader, Jane E.
Lindeman, Geoffrey J.
NATURE MEDICINE, 2016, 22 (08) : 933 - +
[2] RANK ligand is a target for breast cancer prevention in BRCA1 mutation carriers
Lindeman, G. J.
Nolan, E.
Pal, B.
Vaillant, F.
Giner, G.
Whitehead, L.
Mann, G. B.
Lok, S. W.
Shackleton, K.
Smyth, G. K.
Visvader, J. E.
CANCER RESEARCH, 2016, 76
[3] RANK LIGAND AS A TARGET FOR BREAST CANCER PREVENTION IN BRCA1 MUTATION CARRIERS
Nolan, E.
Vaillant, F.
Branstetter, D.
Pal, B.
Giner, G.
Whitehead, L.
Lok, S. W.
Mann, G. B.
ConFab, K.
Rohrbach, K.
Huang, L. Y.
Soriano, R.
Smyth, G. K.
Dougall, W. C.
Visvader, J. E.
Lindeman, Geoffrey
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 97 - 97
[4] RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers
Lindeman, G. J.
Nolan, E.
Vaillant, F.
Branstetter, D.
Pal, B.
Giner, G.
Whitehead, L.
Lok, S. W.
Mann, G. B.
Rohrbach, K.
Huang, L-Y
Soriano, R.
Smyth, G. K.
Dougall, W. C.
Visvader, J. E.
CANCER RESEARCH, 2017, 77
[5] Drug repurposing for breast cancer prevention in BRCA1-mutation carriers
Nolan, E.
Visvader, J. E.
Lindeman, G. J.
EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 760 - 760
[6] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS
FORD, D
EASTON, DF
BISHOP, DT
NAROD, SA
GOLDGAR, DE
HAITES, N
MILNER, B
ALLAN, L
PONDER, BAJ
PETO, J
SMITH, S
STRATTON, M
LENOIR, GM
FEUNTEUN, J
LYNCH, H
ARASON, A
BARKARDOTTIR, R
EGILSSON, V
BLACK, DM
KELSELL, D
SPURR, N
DEVILEE, P
CORNELISSE, CJ
VARSEN, H
BIRCH, JM
SKOLNICK, M
SANTIBANEZKOREF, MS
TEARE, D
STEEL, M
PORTER, D
COHEN, BB
CAROTHERS, A
SMYTH, E
WEBER, B
NEWBOLD, B
BOEHNKE, M
COLLINS, FS
CANNONALBRIGHT, LA
GOLDGAR, D
LANCET, 1994, 343 (8899): : 692 - 695
[7] The Expression of Phosphorylated mTOR in Breast Cancer from BRCA1-Mutation Carriers
Korski, K.
Malicka, A.
Wysocki, P.
CANCER RESEARCH, 2009, 69 (24) : 694S - 694S
[8] Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis
Vaziri, SAJ
Krumroy, LM
Elson, P
Budd, GT
Darlington, G
Myles, J
Tubbs, RR
Casey, G
CLINICAL CANCER RESEARCH, 2001, 7 (07) : 1937 - 1945
[9] Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
Lips, E. H.
Mulder, L.
Oonk, A.
van der Kolk, L. E.
Hogervorst, F. B. L.
Imholz, A. L. T.
Wesseling, J.
Rodenhuis, S.
Nederlof, P. M.
BRITISH JOURNAL OF CANCER, 2013, 108 (10) : 2172 - 2177
[10] Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
E H Lips
L Mulder
A Oonk
L E van der Kolk
F B L Hogervorst
A L T Imholz
J Wesseling
S Rodenhuis
P M Nederlof
British Journal of Cancer, 2013, 108 : 2172 - 2177

← 1 2 3 4 5 →